Table 1.

Clinical data of patients with COVID-19 presenting cutaneous manifestations.

Patients	Hospital unit	Extracutaneous manifestations related to COVID-19	Cutaneous manifestations occurring concomitantly to COVID-19	Delay between first COVID-19 extracutaneous symptoms and rash onset (days)	Drugs used before the occurrence of the rash	Delay between initiation of each treatments and the onset of the rash (days)	Hypereosinophilia (>0,5G/L)
Patient 1	ICU	Severe bilateral pneumonia requiring orotracheal intubation	Maculopapular exanthema of trunk and shoulders	25	Ceftriaxone Azithromycine Hydroxychloroquine	25	Yes
					Tazocilline Linézolide Valaciclovir	20
Patient 2	ICU	Severe bilateral pneumonia requiring oxygen therapy	Diffuse maculopapular exanthema	20	Amoxicilline/clavulanic acid	20	No
					Ceftriaxone Spiramycine Azithromycine Hydroxychloroquine	3
Patient 3	CMU	Flu-like symptoms	Maculopapular exanthema of abdomen and limbs and bilateral livedo of knees Pruritus	5	Paracetamol	0	No
Patient 4	CMU	Flu-like symptoms	Maculopapular exanthema of trunk and limbs with slight pruritus	30	Ceftriaxone Azithromycine	30	Yes
Patient 5	ICU	Severe bilateral pneumonia requiring orotracheal intubation	Maculopapular exanthema of trunk and limbs	35	Ceftriaxone Azithromycine Linézolide	35	No
					Tazocilline Aciclovir	25
Patient 6	ICU	Severe bilateral pneumonia requiring oxygen therapy	Diffuse maculopapular exanthema Pruritus	30	Ceftriaxone Spiramycine Hydroxychloroquine	20	Yes
					Tazocilline Linézolide	5

ICU, intensive care unit; CMU, conventional medicine unit; COVID-19, coronavirus disease 2019.